Xingjiang Xiong1, Pengqian Wang2, Lian Duan3, Wei Liu4, Fuyong Chu4, Shengjie Li5, Xiaoke Li6, Kelei Su7, Hu You8, Yanwei Xing9. 1. Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: xiongxingjiangtcm@163.com. 2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. 3. Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. 4. Department of Cardiology, Traditional Chinese Medicine Hospital of Beijing, Beijing University of Chinese Medicine, Beijing, China. 5. Department of Biological Science and Technology, School of Life Sciences, Tsinghua University, Beijing, China; Department of Molecular Biology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. 6. Bio-organic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, Belmont, USA. 7. Department of Respiration, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. 8. Department of Chinese Medicine, Nanjing Benq Hospital, Nanjing Medical University, Nanjing, China; College of Basic Medicine, Nanjing University of Chinese Medicine, Nanjing, China. Electronic address: 364577807@qq.com. 9. Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: xingyanwei12345@163.com.
Abstract
BACKGROUND: Xiao Yao San (XYS) is thought to be beneficial for the treatment of hypertension in China. PURPOSE: A systematic review and meta-analysis was performed to evaluate the efficacy and safety of XYS in hypertension. STUDY DESIGN: A comprehensive literature search was conducted in 7 electronic databases for randomized controlled trials from their inception until January 7, 2019. METHODS: Methodological quality was assessed independently using the Cochrane Handbook for Systematic Reviews of Interventions. RESULTS: A total of 17 trials including 1460 hypertensive patients met the selection criteria. Pooled analysis favored XYS plus antihypertensive drugs on blood pressure (BP), Hamilton anxiety scale, self-rating anxiety scale, self-rating depression scale, 9-item patient health questionnaire scale, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, homocysteine, and C-reactive protein. No significant difference between XYS plus antihypertensive drugs and antihypertensive drugs on major cardiovascular and cerebrovascular events was identified. XYS was well tolerated in the treatment of hypertension. CONCLUSION: XYS adjuvant to antihypertensive drugs maybe beneficial for hypertensive patients in lowering BP, improving depression, regulating blood lipids, and inhibiting inflammation. However, the efficacy and safety of XYS are still uncertain due to methodological shortcomings. More long-term, randomized, double-blinded clinical trials are needed in future studies.
BACKGROUND: Xiao Yao San (XYS) is thought to be beneficial for the treatment of hypertension in China. PURPOSE: A systematic review and meta-analysis was performed to evaluate the efficacy and safety of XYS in hypertension. STUDY DESIGN: A comprehensive literature search was conducted in 7 electronic databases for randomized controlled trials from their inception until January 7, 2019. METHODS: Methodological quality was assessed independently using the Cochrane Handbook for Systematic Reviews of Interventions. RESULTS: A total of 17 trials including 1460 hypertensivepatients met the selection criteria. Pooled analysis favored XYS plus antihypertensive drugs on blood pressure (BP), Hamilton anxiety scale, self-rating anxiety scale, self-rating depression scale, 9-item patient health questionnaire scale, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, homocysteine, and C-reactive protein. No significant difference between XYS plus antihypertensive drugs and antihypertensive drugs on major cardiovascular and cerebrovascular events was identified. XYS was well tolerated in the treatment of hypertension. CONCLUSION:XYS adjuvant to antihypertensive drugs maybe beneficial for hypertensivepatients in lowering BP, improving depression, regulating blood lipids, and inhibiting inflammation. However, the efficacy and safety of XYS are still uncertain due to methodological shortcomings. More long-term, randomized, double-blinded clinical trials are needed in future studies.